Pharsight

Drugs that contain Mavacamten

1. List of Camzyos drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(11 years from now)

Do you want to check out CAMZYOS patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 28, 2029
New Chemical Entity Exclusivity (NCE) Apr 28, 2027

NCE-1 date: 2026-04-28

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE;ORAL

More Information on Dosage

CAMZYOS family patents

12

United States

4

Australia

3

Japan

3

Korea, Republic of

3

Israel

2

China

2

Singapore

EA

2

EA

2

European Union

1

Spain

1

Hong Kong

1

Dominican Republic

1

Philippines

1

Malaysia

1

Denmark

1

RS

1

Poland

1

Brazil

1

Canada

1

Ukraine

1

Morocco

1

New Zealand

1

Croatia

1

Guatemala

1

Peru

1

Chile

1

Portugal

1

Mexico

1

Costa Rica

1

South Africa

1

Lithuania

1

Tunisia

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic